Patents by Inventor Haiyan Jiang

Haiyan Jiang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ASSAYS TO MONITOR BLEEDING DISORDERS
    Publication number: 20200386774
    Abstract: The present invention provides methods of dosing Factor VIII or Factor IX chimeric and hybrid polypeptides. The present invention further provides high-sensitivity methods of quantifying an amount of activated FIX protein in a test sample.
    Type: Application
    Filed: April 14, 2020
    Publication date: December 10, 2020
    Inventors: Jurg SOMMER, Haiyan JIANG, Xin ZHANG, Buyue YANG, Glenn PIERCE
  • METHODS AND COMPOSITIONS FOR INCREASING RNA ACTIVITY IN A CELL
    Publication number: 20200318140
    Abstract: Disclosed herein are methods and compositions for increasing RNA activity in a cell.
    Type: Application
    Filed: April 3, 2020
    Publication date: October 8, 2020
    Inventors: Siyuan Tan, Dale Ando, Andreas Reik, Linhong Li, Madhusudan V. Peshwa, Haiyan Jiang
  • Assays to monitor bleeding disorders
    Patent number: 10656167
    Abstract: The present invention provides methods of dosing Factor VIII or Factor IX chimeric and hybrid polypeptides. The present invention further provides high-sensitivity methods of quantifying an amount of activated FIX protein in a test sample.
    Type: Grant
    Filed: July 25, 2012
    Date of Patent: May 19, 2020
    Assignee: BIOVERATIV THERAPEUTICS INC.
    Inventors: Jurg Sommer, Haiyan Jiang, Xin Zhang, Buyue Yang, Glenn Pierce
  • FACTOR VIII COMPOSITIONS AND METHODS OF MAKING AND USING SAME
    Publication number: 20200087379
    Abstract: The present invention relates to compositions comprising factor VIII coagulation factors linked to extended recombinant polypeptide (XTEN), isolated nucleic acids encoding the compositions and vectors and host cells containing the same, and methods of making and using such compositions in treatment of factor VIII-related diseases, disorders, and conditions.
    Type: Application
    Filed: July 25, 2019
    Publication date: March 19, 2020
    Inventors: Volker Schellenberger, Pei-Yun Chang, Fatbardha Varfaj, Sheng Ding, Joshua Silverman, Chia-wei Wang, Benjamin Spink, Willem P. Stemmer, Nathan Geething, John Kulman, Tongyao Liu, Garabet G. Toby, Haiyan Jiang, Robert Peters, Deping Wang, Baisong Mei
  • Factor IX polypeptides and methods of use thereof
    Patent number: 10568943
    Abstract: The present invention provides methods of administering Factor IX; methods of administering chimeric and hybrid polypeptides comprising Factor IX; polynucleotides encoding such chimeric and hybrid polypeptides; cells comprising such polynucleotides; and methods of producing such chimeric and hybrid polypeptides using such cells.
    Type: Grant
    Filed: February 8, 2019
    Date of Patent: February 25, 2020
    Assignee: BIOVERATIV THERAPEUTICS INC.
    Inventors: Glenn Pierce, Samantha Truex, Robert T. Peters, Haiyan Jiang
  • Factor IX polypeptides and methods of use thereof
    Patent number: 10561714
    Abstract: The present invention provides methods of administering Factor IX; methods of administering chimeric and hybrid polypeptides comprising Factor IX; polynucleotides encoding such chimeric and hybrid polypeptides; cells comprising such polynucleotides; and methods of producing such chimeric and hybrid polypeptides using such cells.
    Type: Grant
    Filed: February 6, 2018
    Date of Patent: February 18, 2020
    Assignee: Bioverativ Therapeutics Inc.
    Inventors: Glenn Pierce, Samantha Truex, Robert T. Peters, Haiyan Jiang
  • Factor IX polypeptides and methods of use thereof
    Patent number: 10548954
    Abstract: The present invention provides methods of administering Factor IX; methods of administering chimeric and hybrid polypeptides comprising Factor IX; polynucleotides encoding such chimeric and hybrid polypeptides; cells comprising such polynucleotides; and methods of producing such chimeric and hybrid polypeptides using such cells.
    Type: Grant
    Filed: February 8, 2019
    Date of Patent: February 4, 2020
    Assignee: BIOVERATIV THERAPEUTICS INC.
    Inventors: Glenn Pierce, Samantha Truex, Robert T. Peters, Haiyan Jiang
  • Factor VIII-XTEN fusions and uses thereof
    Patent number: 10548953
    Abstract: The present invention provides chimeric proteins comprising a Factor VIII (FVIII) polypeptide and XTEN polypeptides. The FVIII polypeptide can have a reduced affinity for von Willebrand Factor (VWF). XTEN polypeptides of appropriate sizes are inserted into the FVIII polypeptide at particular locations in order to extend the half-life of the FVIII polypeptide. The invention also includes nucleotides, vectors, host cells, and methods of using the chimeric proteins, e.g., to treat bleeding diseases and disorders.
    Type: Grant
    Filed: August 14, 2014
    Date of Patent: February 4, 2020
    Assignee: BIOVERATIV THERAPEUTICS INC.
    Inventors: Tongyao Liu, Pei-Yun Chang, John Kulman, Volker Schellenberger, Haiyan Jiang, Robert T. Peters, Ekta Seth Chhabra
  • METHODS OF USING A FIXED DOSE OF A CLOTTING FACTOR
    Publication number: 20200030420
    Abstract: The present invention provides methods of administering a clotting factor by a fixed dosing regimen; methods of reducing, ameliorating, or preventing one or more symptoms of a bleeding disease or disorder; and a kit comprising a dotting factor useful for a fixed dosing regimen. While plasma-derived and recombinant clotting factor products allow hemophilia patients to live longer and healthier, hemophilia still remains one of the most costly and complex conditions to manage.
    Type: Application
    Filed: July 3, 2019
    Publication date: January 30, 2020
    Inventors: Haiyan JIANG, Lei DIAO, Shuanglian LI, Paula COBB
  • POPULATION PHARMACOKINETICS TOOLS AND USES THEREOF
    Publication number: 20190362856
    Abstract: The present invention is directed to computer based pharmacokinetics systems, such as, web-based pharmacokinetics systems, and their use to predict a dose and a dosing interval for a patient in need of a clotting factor therapy.
    Type: Application
    Filed: May 6, 2019
    Publication date: November 28, 2019
    Inventor: Haiyan Jiang
  • FACTOR VIII COMPOSITIONS AND METHODS OF MAKING AND USING SAME
    Publication number: 20190315835
    Abstract: The present invention relates to compositions comprising factor VIII coagulation factors linked to extended recombinant polypeptide (XTEN), isolated nucleic acids encoding the compositions and vectors and host cells containing the same, and methods of making and using such compositions in treatment of factor VIII-related diseases, disorders, and conditions.
    Type: Application
    Filed: March 29, 2019
    Publication date: October 17, 2019
    Inventors: Volker SCHELLENBERGER, Pei-Yun CHANG, Fatbardha VARFAJ, John KULMAN, Tongyao LIU, Garabet G. TOBY, Haiyan JIANG, Robert PETERS, Deping WANG, Baisong MEI, Joshua SILVERMAN, Chia-Wei WANG, Benjamin SPINK, Nathan GEETHING
  • Factor VIII compositions and methods of making and using same
    Patent number: 10421798
    Abstract: The present invention relates to compositions comprising factor VIII coagulation factors linked to extended recombinant polypeptide (XTEN), isolated nucleic acids encoding the compositions and vectors and host cells containing the same, and methods of making and using such compositions in treatment of factor VIII-related diseases, disorders, and conditions.
    Type: Grant
    Filed: July 11, 2012
    Date of Patent: September 24, 2019
    Assignee: BIOVERATIV THERAPEUTICS INC.
    Inventors: Volker Schellenberger, Pei-Yun Chang, Fatbardha Varfaj, Sheng Ding, Joshua Silverman, Chia-wei Wang, Benjamin Spink, Willem P. Stemmer, Volker Schellenberger, Nathan Geething, John Kulman, Tongyao Liu, Garabet G. Toby, Haiyan Jiang, Robert Peters, Deping Wang, Baisong Mei
  • FACTOR VIII-FC CHIMERIC AND HYBRID POLYPEPTIDES, AND METHODS OF USE THEREOF
    Publication number: 20190262429
    Abstract: The present invention provides methods of administering Factor VIII; methods of administering chimeric and hybrid polypeptides comprising Factor VIII; chimeric and hybrid polypeptides comprising Factor VIII: polynucleotides encoding such chimeric and hybrid polypeptides; cells comprising such polynucleotides; and methods of producing such chimeric and hybrid polypeptides using such cells.
    Type: Application
    Filed: February 7, 2019
    Publication date: August 29, 2019
    Inventors: Jennifer A. DUMONT, Susan LOW, Alan J. BITONTI, Glenn PIERCE, Alvin LUK, Haiyan JIANG, Byron MCKINNEY, Matt OTTMER, Jurg SOMMER, Karen NUGENT, Lian LI, Robert PETERS
  • Methods of using a fixed dose of a clotting factor
    Patent number: 10391152
    Abstract: The present invention provides methods of administering a clotting factor by a fixed dosing regimen; methods of reducing, ameliorating, or preventing one or more symptoms of a bleeding disease or disorder; and a kit comprising a dotting factor useful for a fixed dosing regimen. While plasma-derived and recombinant clotting factor products allow hemophilia patients to live longer and healthier, hemophilia still remains one of the most costly and complex conditions to manage.
    Type: Grant
    Filed: October 18, 2013
    Date of Patent: August 27, 2019
    Assignee: Bioverativ Therapeutics Inc.
    Inventors: Haiyan Jiang, Lei Diao, Shuanglian Li, Paula Cobb
  • METHODS OF REDUCING IMMUNOGENICITY AGAINST FACTOR VIII IN INDIVIDUALS UNDERGOING FACTOR VIII THERAPY
    Publication number: 20190241960
    Abstract: The present disclosure provides methods of administering chimeric and hybrid Factor VIII (FVIII) polypeptides comprising FVIII and Fc to subjects at risk of developing inhibitory FVIII immune responses, including anti-FVIII antibodies and/or cell-mediated immunity. The administration is sufficient to promote coagulation and to induce immune tolerance to FVIII. The chimeric polypeptide can comprise full-length FVIII or a FVIII polypeptide containing a deletion, e.g., a full or partial deletion of the B domain.
    Type: Application
    Filed: January 11, 2019
    Publication date: August 8, 2019
    Inventors: Haiyan Jiang, Tongyao Liu, Sriram Krishnamoorthy, Neil Josephson, Glenn Pierce
  • FACTOR IX POLYPEPTIDES AND METHODS OF USE THEREOF
    Publication number: 20190192641
    Abstract: The present invention provides methods of administering Factor IX; methods of administering chimeric and hybrid polypeptides comprising Factor IX; polynucleotides encoding such chimeric and hybrid polypeptides; cells comprising such polynucleotides; and methods of producing such chimeric and hybrid polypeptides using such cells.
    Type: Application
    Filed: February 8, 2019
    Publication date: June 27, 2019
    Inventors: Glenn Pierce, Samantha Truex, Robert T. Peters, Haiyan Jiang
  • FACTOR IX POLYPEPTIDES AND METHODS OF USE THEREOF
    Publication number: 20190192640
    Abstract: The present invention provides methods of administering Factor IX; methods of administering chimeric and hybrid polypeptides comprising Factor IX; polynucleotides encoding such chimeric and hybrid polypeptides; cells comprising such polynucleotides; and methods of producing such chimeric and hybrid polypeptides using such cells.
    Type: Application
    Filed: February 8, 2019
    Publication date: June 27, 2019
    Inventors: Glenn Pierce, Samantha Truex, Robert T. Peters, Haiyan Jiang
  • Population pharmacokinetics tools and uses thereof
    Patent number: 10325687
    Abstract: The present invention is directed to computer based pharmacokinetics systems, such as. web-based pharmacokinetics systems, and their use to predict a dose and a dosing interval for a patient in need of a clotting factor therapy.
    Type: Grant
    Filed: December 6, 2014
    Date of Patent: June 18, 2019
    Assignee: Bioverativ Therapeutics Inc.
    Inventor: Haiyan Jiang
  • Methods of reducing immunogenicity against factor VIII in individuals undergoing factor VIII therapy
    Patent number: 10221455
    Abstract: The present disclosure provides methods of administering chimeric and hybrid Factor VIII (FVIII) polypeptides comprising FVIII and Fc to subjects at risk of developing inhibitory FVIII immune responses, including anti-FVIII antibodies and/or cell-mediated immunity. The administration is sufficient to promote coagulation and to induce immune tolerance to FVIII. The chimeric polypeptide can comprise full-length FVIII or a FVIII polypeptide containing a deletion, e.g., a full or partial deletion of the B domain.
    Type: Grant
    Filed: January 12, 2013
    Date of Patent: March 5, 2019
    Assignees: BIOVERATIV THERAPEUTICS INC., PUGET SOUND BLOOD CENTER
    Inventors: Haiyan Jiang, Tongyao Liu, Sriram Krishnamoorthy, Neil Josephson, Glenn Pierce
  • FACTOR VIII CHIMERIC AND HYBRID POLYPEPTIDES, AND METHODS OF USE THEREOF
    Publication number: 20180360982
    Abstract: The present invention provides methods of administering Factor VIII (processed FVIII, single chain FVIII, or a combination thereof); methods of administering chimeric and hybrid polypeptides comprising Factor VIII; chimeric and hybrid polypeptides comprising Factor VIII; polynucleotides encoding such chimeric and hybrid polypeptides; cells comprising such polynucleotides; and methods of producing such chimeric and hybrid polypeptides using such cells.
    Type: Application
    Filed: May 29, 2018
    Publication date: December 20, 2018
    Applicant: Bioverativ Therapeutics Inc.
    Inventors: Jennifer A. DUMONT, Susan LOW, Alan J. BITONTI, Glenn PIERCE, Alvin LUK, Haiyan JIANG, Byron MCKINNEY, Matt OTTMER, Jurg SOMMER, Karen NUGENT, Lian LI, Robert T. PETERS